New tumor products
Our tumor marker offering is growing with the introduction of squamous cell carcinoma (SCC) antibodies and a recombinant neuron-specific enolase (NSE) antigen.
SCC is typically measured together with other tumor markers, and it is also used in monitoring disease recurrence and response to therapy.
The good performance of the new MedixMAB SCC antibodies has been proven in patient sample evaluations.
Neuron-specific enolase (NSE) has been detected in patients with certain tumors, mostly with neuroblastoma and small cell lung cancer.
Measurement of NSE levels in patients with these two diseases can provide information about the extent of the disease and the patient’s prognosis, as well as about the patient’s response to treatment.
NSE is also used in neurology to assess the extent of traumatic brain injury.
The new recombinant NSE antigen is suitable as a control antigen and combines well with the existing MedixMAB antibodies for NSE detection.
If you are developing tumor immunoassays and are interested in these markers, please contact your local sales representative to discuss your sample evaluation needs.
Please see below our SCC and NSE products:
|Anti-h SCC 11801 SPTN-5
Anti-h SCC 11802 SPTN-5
Anti-h SCC 11803 SPTN-5
Anti-h SCC 11804 SPTN-5